Viewing Study NCT00655161


Ignite Creation Date: 2025-12-24 @ 12:44 PM
Ignite Modification Date: 2025-12-28 @ 12:26 AM
Study NCT ID: NCT00655161
Status: COMPLETED
Last Update Posted: 2014-01-29
First Post: 2008-04-02
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: A Pilot Phase 2 Trial of the Immunogenicity, and Safety of GI-4000; an Inactivated Recombinant S. Cerevisiae Expressing Mutant Ras Protein, as Consolidation Therapy Following Curative Treatment for Stage I-III Non-Small Cell Lung Cancer (NSCLC) With Tumor Sequence Confirmation of K-ras Mutation
Sponsor: GlobeImmune
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module Annotation Module